Searched for
AJANTA PHARMA REGULATORY FILING
You could get thousands back in tax refunds, if you know where to look- Ahead of Market: 10 things that will decide stock market action on TuesdayIndian equities ended lower, snapping a two-day rally as escalating Iran-US tensions and profit booking weighed on sentiment. Sensex fell 3...
- ITR filing guide: Know when tax return filing is mandatory, who needs to file and who is exemptIndividuals and Hindu Undivided Families (HUFs) are required to file income tax returns (ITR) if their total taxable income before the appl...
- AMFI reshuffle: Hindustan Copper among 6 smallcap stocks that may get upgraded to midcapSix smallcap stocks, including Hindustan Copper and NLC India, may move to midcap in AMFI’s H2 CY26 reshuffle, as per Nuvama Institutional ...
- Strides Pharma sells majority stake in arm Pivot Path for Rs 100 croreStrides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital ...
- Trade disruptions, API dependence, compliance costs: Pharma MSMEs spell out policy priorities on World MSME DayIndian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry represent...
- Power Grid of India board okays raising borrowing limit to Rs 2.2 lakh crThe board of Power Grid Corporation has approved a substantial raise in its borrowing limit to Rs 2.2 lakh crore, up from Rs 1.8 lakh crore...
- Power Grid of India board okays raising borrowing limit to Rs 2.2 lakh crorePower Grid Corporation's board has greenlit a significant increase in its borrowing limit to Rs 2.2 lakh crore, pending shareholder approva...
- Alembic Pharma gets USFDA nod for generic influenza treatment drugAlembic Pharmaceuticals has secured USFDA approval for its generic oseltamivir phosphate oral suspension, a key treatment for influenza. Th...
- Lupin gets USFDA tentative approval for prostate cancer treatment drugIndian pharmaceutical giant Lupin Ltd has secured tentative approval from the US FDA for its generic enzalutamide tablets, a crucial treatm...
- ITR filing 2026: Avoid these 8 costly mistakes before you submit your tax return
- Suryoday SFB board approves plans to raise up to Rs 500 crore via equity and debtSuryoday Small Finance Bank's board has greenlit plans to raise up to Rs 300 crore through share sales and Rs 200 crore via debt instrument...
- India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...
- Honasa Consumer to buy 58% stake in Fluence Pharma at Rs 135-crore enterprise valueMamaearth's parent company, Honasa Consumer, is acquiring a majority stake in nutraceuticals brand Fluence Pharma for ₹135 crore. This stra...
- NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chainNiti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think ta...
- Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
- USFDA concludes inspection at Jubilant HollisterStier's Spokane plant with 8 observationsJubilant Pharmova announced its US subsidiary, Jubilant HollisterStier LLC, underwent a USFDA inspection. The facility in Spokane, Washingt...
- Aurobindo Pharma clears key US hurdle in Lannett acquisition, closing expected soonIndian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federa...
- Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, VedantaIndian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but unce...
Load More
